[Pulmonary hypertension associated with interstitial lung diseases: current state of the art].

Authors

Adrien Lozina, Quentin Maloir, Gilles Parzibut, Fanny Gester, Raluca Elena Dulgheru, Hélène Petitjean, Cédric Davidsen, Patrizio Lancellotti, Céline Defourny, Colin Desir, Perrine Canivet, Renaud Louis, Julien Guiot

Published in

Revue medicale de Liege. Volume 81. Issue 10. Pages 589-596.

Abstract

Pulmonary hypertension associated with interstitial lung diseases (PH-ILD) is a common and severe complication of interstitial lung diseases. Diagnosis is challenging and relies on a combination of clinical, functional, biological, radiological and echocardiographic findings. Definitive diagnosis is established by right heart catheterisation, which confirms the presence of pre-capillary pulmonary hypertension associated with increased pulmonary vascular resistance. Until 2021, and the INCREASE study, all randomised controlled trials evaluating therapies approved for pulmonary arterial hypertension in patients with PH-ILD yielded disappointing results. However, recent advances exploring the potential of novel therapeutic strategies have renewed interest in PH-ILD, with a progressive paradigm shift opening new perspectives for a condition that was until recently associated with a poor prognosis.

PMID:
42861537
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.